Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab + FOLFIRI versus cetuximab/bevacizumab + FOLFIRI in recurrent or metastatic RAS/BRAF wild-type colorectal cancer
2024-513853-66-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial of amivantamab, cetuximab, bevacizumab, irinotecan, fluorouracil and 1 more in colorectal cancer (CRC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Progression-free survival and Overall survival. Planned start Feb 2025; status: authorised.
02
Drugs
amivantamabcetuximabbevacizumabirinotecanfluorouracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-513853-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513853-66-00.